Low-cost detection of dementia using electronic health records data: validation and testing of the eRADAR algorithm in a pragmatic, patient-centered trial.

使用电子健康记录数据低成本检测痴呆症：在务实、以患者为中心的试验中验证和测试 eRADAR 算法。

• 批准号: 10443874
• 负责人: Deborah E. Barnes
• 金额: $ 82.66万
• 依托单位: KAISER FOUNDATION RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-30 至 2026-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10443874
• 关键词: Academic Medical Centers; Algorithms; Alzheimer' s Disease; Alzheimer' s disease risk; California; Caregivers; Clinic; Clinical; Clinical Research; Communities; Data; Data Element; Dementia; Detection; Development; Diabetes Mellitus; Diagnosis; Disease; Early Diagnosis; Education; Electronic Health Record; Emergency department visit; Equilibrium; Ethnic Origin; Family; Family member; Funding; Goals; Health Services Accessibility; Healthcare Systems; Impaired cognition; Inpatients; Integrated Delivery of Health Care; Intervention; Interview; Laboratories; Machine Learning; Measures; Mental Depression; Participant; Patient Care; Patient Education; Patients; Pattern; Performance; Persons; Population Heterogeneity; Pragmatic clinical trial; Predictive Value; Primary Health Care; Procedures; Process; Quality of Care; Quality of life; Race; Randomized; Randomized Controlled Trials; Recommendation; Request for Applications; Research Design; Research Support; Retrospective Studies; Risk; Role; San Francisco; Sensitivity and Specificity; Services; Stroke; Subgroup; Surveys; Symptoms; System; Testing; Traumatic Brain Injury; Underweight; Universities; Validation; Visit; Washington; Work; base; care providers; clinical care; comparison intervention; cost; dementia risk; design; electronic structure; experience; follow-up; formative assessment; health care service utilization; high risk; human old age (65+); improved; medication compliance; neuroimaging; outreach; patient oriented; patient population; patient subsets; pragmatic implementation; pragmatic trial; preventive intervention; primary outcome; satisfaction; secondary outcome; sex; tool; treatment arm; treatment as usual; usual care arm

Nearly half of people currently living with dementia have not received a diagnosis, delaying access to treatment as well as education and support for the patient and family. Thus, NIA has requested applications to support pragmatic clinical trials of low-cost tools to improve detection of cognitive decline in clinical settings (RFA-AG- 20-051). With pilot funding from NIA, we used machine learning to develop a low-cost tool called eRADAR (electronic health record Risk of Alzheimer's and Dementia Assessment Rule), which uses easily accessible information in the electronic health record (EHR) to help identify patients with undiagnosed dementia. In addition, we interviewed patients, caregivers, clinicians, and healthcare system leaders to inform pragmatic implementation of eRADAR in clinical settings. Stakeholders felt strongly that such a tool should be implemented through primary care, in the context of existing clinical relationships, and would need to be accompanied by additional support for patients and clinicians. Our current proposal is heavily informed by this development work. In Aim 1, we will use EHR data to evaluate eRADAR's performance in different patient subgroups, including by race/ethnicity, in two healthcare systems to inform selection of cut- points for use in clinical settings. We will select an optimal cut-point to use for targeted dementia assessment with stakeholder input, balancing sensitivity, specificity, and positive predictive value. In Aim 2, we will perform a pragmatic clinical trial to determine whether implementing eRADAR as part of a supported outreach process to high-risk patients improves dementia detection. The setting will be primary care clinics within Kaiser Permanente Washington (KPWA), an integrated healthcare delivery system in Washington State, and the University of California, San Francisco (UCSF), an urban, academic healthcare system with a diverse patient population. The study includes 6 clinics with ~24,000 patients age ≥65. Within each clinic, primary care providers (PCPs) will be randomly assigned to have their patients with high eRADAR scores targeted for outreach (intervention) or to usual care (control). Our clinical research staff—whose roles were designed to reflect existing roles within these healthcare systems to maximize pragmatism—will reach out to patients with high eRADAR scores, conduct an assessment for cognitive impairment, make follow-up recommendations to PCPs, and support patients after diagnosis. Patients with high eRADAR scores in both treatment arms will be followed to determine the impact of eRADAR on new diagnoses of dementia (primary outcome) as assessed from the EHR (again, to maximize pragmatism). In Aim 3, we will explore the impact of eRADAR implementation on secondary outcomes including healthcare utilization and experience of patients and family members. If this pragmatic trial is successful, the eRADAR tool and process could be spread to other healthcare systems, potentially improving detection of cognitive decline, patient care, and quality of life.

近一半目前患有痴呆症的人没有得到诊断，延误了获得治疗的机会